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Introduction
MAS is serious and severe, sometimes life threatening
complication of sJIA but data about survivor outcomes
are missing.
Objectives
We present 16 year old girl who developed MAS six
years after sJIA was established and whose parents
refused some treatment options.
Methods
Analiysis of clinical outcome and laboratory parametars
in non biologic treated patient with sJIA who developed
MAS.
Results
After episode of fever and exudative pericarditis (cardiac
tamponade) in 2nd and 4th year of life the diagnose of sJIA
was established and steroid and NSAIDs therapy was
introduced. Clinical remission was achieved and lasted
3 years when at the age of years, after moderate respiratory
infection she developed persistant oligoarthritis why meto-
trexate was administrated during one year until disease
remission. She was lost for follow up until admitted to the
hospital due to high grade fever, macular rash, weakness,
oligoarthritis, aphthous stomatitis, cervical limfadenopathy
and pericarditis. The pulses of methyl-prednisolone were
started followed with the oral steroids (2 mg/kg) and
NSAIDs therapy. Episodes of fever, rash and morning
stiffness with elevated values of ESR, CRP and WBC were
still present after 2 weeks why CyA was added. Next
3 weeks she was relatively stabile, but became Coushing-
oid with occasional fever and high blood pressure, In the
fourth week of hospitalization she developed seizures due
to hypertensive encephalopathy (TA 210/160 mmHg).
Intensive antihypertensive and antiedematous therapy has
normalised blood pressure without new episodes of
seizures. After 6 weeks of treatment she developed inten-
sive epigastric pain and diffuse tenderness in the abdomen
(peritonitis) with diffuse purpuric skin lesions all over the
body. Laboratory results have shown low PLT count,
hypertriglyceridiemia highly elevated liver enzymes, feritin
and LDH (10403 mmol/L) and profound hyponatriemia
(112 mmol/l). Diagnose of MAS was established and due
to oliguria and her serous condition hemodiafiltration was
initiated together with etoposide and VP16. During next
2 months she was in ICU and have had imapared coagula-
tion parameters and developed necrotic-vasculitis skin
changes. Parents refused implementation of any additional
immunosuppresive or biologic therapy except shourt
course of Thalidomide. Due to a chronic renal failure she
is still on regular hemodialysis. During follow up period
she never developed new epizodes of arthritis but have
developed amyloidosis (with constrictive pericarditis and
cardiomyopathy), chronic renal failure and seizures.
Conclusion
MAS is major cause of mortality in patients with sJIA.
Data about MAS survivors and their outcome in corre-
lation to treatment aproach are missing especially for
patients not treated with biologics.
Disclosure of interest
None declared.Pediatric Rheumatology, Clinic of Pediatrics, Clinical Center Nis, Nis, Serbia
Lazarevic and Vojinovic Pediatric Rheumatology 2013, 11(Suppl 2):P53
http://www.ped-rheum.com/content/11/S2/P53
© 2013 Lazarevic and Vojinovic; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P53
Cite this article as: Lazarevic and Vojinovic: PReS-FINAL-2040: Outcome
of macrophage activation syndrom (MAS) in systemic juvenile idiopatic
arthritis (SJIA) in non biologic treated patient. Pediatric Rheumatology
2013 11(Suppl 2):P53.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lazarevic and Vojinovic Pediatric Rheumatology 2013, 11(Suppl 2):P53
http://www.ped-rheum.com/content/11/S2/P53
Page 2 of 2
